Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on May 6th, 2024 | 07:15 CEST
Bayer on the path out of crisis. With their oncology pipelines, are Defence Therapeutics and BioNTech also on the verge of a turnaround?
After several years of stumbling from one crisis to another, pharmaceutical and agrochemical giant Bayer is now showing signs of a recovery on the horizon. As Bayer navigates its long and rocky road out of the crisis, investors and industry experts are now turning their attention to two other exciting biotech companies: Defence Therapeutics and BioNTech. Both companies, which have caused a sensation in the past mainly due to their revolutionary approaches in cancer therapy, could follow in Bayer's footsteps with their promising oncology pipelines, moving from uncertainty to a bright future.
Read
Commented by Armin Schulz on April 30th, 2024 | 07:00 CEST
Evotec, Vidac Pharma, BioNTech - The billion-dollar race for cancer therapy
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this.
Read
Commented by Armin Schulz on April 29th, 2024 | 06:45 CEST
Shell, Saturn Oil + Gas, BP - Oil price soon at USD 100? Oil defies US inflation
Last Friday, the oil price rose despite the negative impact of the latest inflation data from the US. These figures have dampened hopes of swift interest rate cuts by the FED, usually a catalyst for increasing oil demand. Tensions in the Middle East continue to contribute to uncertainty. Some analysts, including those at JP Morgan, are even speculating on a potential rise in the Brent oil price up to USD 100, driven in part by Russia's surprise announcement of further production cuts. If the oil price rises to USD 100, oil companies' profits would soar. We are therefore taking a look at three companies today.
Read
Commented by Armin Schulz on April 23rd, 2024 | 07:15 CEST
RWE, Kraken Energy, Nel ASA - Germany's industry under pressure
Germany is pursuing its own path in energy policy and will rely entirely on renewable energies in future. Robert Habeck emphasized that Germany is now independent of Russian gas. However, there is no talk of independence, as Germany has become a net importer of electricity, indirectly importing gas from Russia and even nuclear power. This is because the energy storage facilities in Germany for renewable energies are not even sufficient for one hour. In addition, Germany has some of the highest electricity prices, which is already prompting industry to relocate some of its production abroad. Nuclear power is an emission-free alternative, and many power plants are being built worldwide. Uranium could become scarce here. Whether hydrogen can solve the energy storage problem is currently questionable.
Read
Commented by Armin Schulz on April 17th, 2024 | 06:45 CEST
Barrick Gold, Globex Mining, BP - Commodities In the spotlight: Supercycle started?
Global demand for commodities is reaching new heights, partly driven by increasing geopolitical tensions. The exchange of attacks between Iran and Israel is a case in point. This conflict, deeply rooted in religious and political differences, continues to escalate and could have far-reaching consequences for international stability and commodity markets. With this latest escalation of the Middle East conflict, security aspects in the global competition for important resources such as gold, silver and copper are taking center stage. China is demonstrating its hunger for resources. However, the price of oil has also risen recently. There has long been talk of a commodity supercycle. Perhaps it has now finally begun. Where should one invest now?
Read
Commented by Armin Schulz on April 15th, 2024 | 06:15 CEST
Varta, Carbon Done Right Developments, Bayer - Buy when the cannons are firing?
The stock market is a fascinating place where investors have to weigh up their opportunities and risks. An often-quoted stock market adage is: "Buy when the cannons are firing". The idea behind this is that one can find opportunities for lucrative investments in times of crisis when market sentiment is particularly poor. Warren Buffett also supports the idea of buying securities or companies at times when the majority of investors are pessimistic, causing prices to fall below the actual value of the investments. He said: "Be greedy when others are fearful and be fearful when others are greedy." We have selected three candidates who have recently lost ground and shed light on whether an investment is worthwhile.
Read
Commented by Armin Schulz on April 10th, 2024 | 07:30 CEST
Nel ASA, First Hydrogen, Nikola - Hydrogen on the rise
With the development towards a clean and efficient logistics industry, hydrogen is gaining importance as a forward-looking energy carrier. Continuous innovations in fuel cell technology and storage systems are making it increasingly competitive. This technological progress, coupled with government incentives to expand the necessary infrastructure, is paving the way for widespread adaptation in the logistics sector. Pilot projects are already validating the practical suitability and paving the way for more extensive implementation in the logistics sector. Recently, there have been positive signals from the three hydrogen companies we are looking at today.
Read
Commented by Armin Schulz on April 8th, 2024 | 06:30 CEST
Volkswagen, Altech Advanced Materials, RWE - Use the dip in electrification companies for your portfolio
The future is electric. With the growing number of electric vehicles, energy storage technologies are also gaining enormous importance. These technologies form the backbone of a reliable, environmentally friendly energy landscape - they store energy from renewable sources and ensure that electricity flows even when the sun and wind are taking a break. Such progress not only promises a smaller ecological footprint but also a new era of energy independence. We have selected three companies that are helping with electrification.
Read
Commented by Armin Schulz on April 4th, 2024 | 06:30 CEST
BYD, Cardiol Therapeutics, Super Micro Computer - Stock market gains thanks to innovation and specialization
In the dynamic stock market environment, companies that invest in innovative technologies and specialization at an early stage stand out with above-average success. Amazon, once founded as a small online bookstore in a garage, is a shining example of this strategy. Through clever diversification and pioneering work in new technology fields, such as cloud computing with Amazon Web Services, Amazon has developed into one of the most valuable corporations. For investors, Amazon's rise underlines the golden opportunities: those with the foresight to invest in future-oriented companies can achieve above-average profits. We have selected three companies that aim to follow this path or have partially already done so.
Read
Commented by Armin Schulz on April 2nd, 2024 | 06:45 CEST
MorphoSys, Defence Therapeutics, Novo Nordisk - Biotech deals: Corporations on a shopping spree!
In 2023, the volume of business in the pharmaceutical industry, with mergers and acquisitions, reached USD 152 billion despite high interest rates. Experts predict that this momentum could continue as large pharmaceutical companies are facing a wave of patent expiries for their key products that will roll in between 2025 and 2030. Companies are therefore on the lookout for new active ingredients, often by acquiring or licensing developments from smaller biotech companies to compensate for potential revenue shortfalls. There have also been major takeovers in recent months. We take a look at takeover targets and buyers.
Read